Navigation Links
Medicago reports positive Phase I results for its avian flu pandemic vaccine
Date:12/21/2009

- Company's results amongst the best for influenza vaccine manufacturing technologies -

QUEBEC CITY, Dec. 21 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

"We are very pleased with the results from this study. This trial was the first ever clinical evaluation of a plant-based Influenza VLP vaccine and shows that Medicago's vaccine is safe in humans," said Andy Sheldon, President and CEO of Medicago. "We believe our novel vaccine candidate, coupled with our rapid response and low cost manufacturing system offers a preferred option to increase the speed of a public health response in the event of a pandemic outbreak. Looking ahead, the successful completion of this trial should enable us to formalize various partner agreements. It may also allow us to access new sources of non-dilutive funding available through U.S. grant programs and by organizations interested in funding the development of better technologies for pandemic vaccine production."

The Phase I study was designed to investigate the safety of the Company's H5N1 alum-adjuvanted pandemic vaccine candidate and to provide an initial indication of the immune response. A total of 48 healthy volunteers between the ages 18 to 60 received two doses of either Medicago's vaccine at doses of 5, 10 or 20 micrograms (mcg) or a placebo. No serious adverse events were reported during the trial and the vaccine was found to be well tolerated at all three dose levels. Local site reactions were mild and the incidence of systemic side effects was comparable between the H5N1 vaccin
'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
7. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... of patented university inventions licensed to biotechnology firms ... commercialization. To open these roadblocks, the researchers suggest ... the discovery stage could lead to faster commercialization ... derived from discoveries made in university laboratories and ... during clinical trials, which have a high failure ...
(Date:8/20/2014)... first time, chemists have succeeded in measuring vibrational motion ... The study reveals how vibration of a single molecule ... , The study was performed at the University of ... University of Jyvskyl works as a visiting fellow under ... study. The second team was lead by Professor Eric ...
(Date:8/20/2014)... 2014 High performance computing (HPC) ... most complete climate and Earth system model to ... issues. , Eight national laboratories, including Lawrence ... Center for Atmospheric Research, four academic institutions and ... participating national laboratories include Argonne, Brookhaven, Lawrence Berkeley, ...
(Date:8/20/2014)... BOSTON , Aug. 20, 2014  PAREXEL International ... it will be presenting at the Baird Healthcare Conference ... President and Chief Financial Officer, will be making a ... p.m. EDT on Wednesday, Sept. 3, 2014. ... through the "Investors" section of PAREXEL,s website at ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... Reportlinker.com announces that a new market ... Animal Husbandry Equipment ... http://www.reportlinker.com/p0181483/Animal-Husbandry-Equipment-Market-in-United-States-Business-Report-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Livestock ... research of animal husbandry equipment market in ...
... DIEGO, Dec. 13, 2011  Astellas Pharma Inc. (Tokyo: 4503, ... results from an interim analysis of a Phase 2 ... (AML) were presented at the 53rd Annual Meeting of ... California.  Data were also presented from two additional posters: ...
... , Dr. Vivek Desai, MD, Hosmac ... Emeritus, Infosys Technologies Clear winner under Healthcare ... appreciation added to his hat of success at the felicitation ceremony ... Dr. Vivek Desai, Managing Director, Hosmac India Pvt. Ltd. is ...
Cached Biology Technology:Animal Husbandry Equipment Market in United States: Business Report 2011 2Animal Husbandry Equipment Market in United States: Business Report 2011 3Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 2Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 3Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 4Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 5Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 6Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 7Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society 8Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 2Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 3
(Date:8/19/2014)... . Wind ... large amount of electricity is to be produced with renewable ... be stored during productive periods so that these fluctuations can ... adequate for the purpose. Science and industry are therefore working ... systems that used to be too expensive or unsophisticated to ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... have identified a biomarker strongly associated with basal-like ... resistant to many types of chemotherapy. The biomarker, ... for new therapeutics designed to treat this often ... taken from The Cancer Genome Atlas, molecular biologists ... powerful computational and bioinformatics techniques to detect patterns ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... type of sperm a male produces, according to new research ... the Proceedings of the National Academy of Sciences ... sperm of many species of African cichlids. These fish have ... where females mate with many males in quick succession. ...
... certain marginalized groups including the mentally ill, the ... Latinos fare worse than others in the aftermath ... Now, a new study by ... experience greater terrorism-related fears and make more behavioral changes ...
... are killers. They strike without warning, causing ... percent of all deaths in the United States., ... associated with arrhythmias. Their findings, reported in The ... to novel arrhythmia treatments., "The current antiarrhythmic drugs ...
Cached Biology News:The more promiscuous the female, the speedier the sperm 2Disabled and other vulnerable groups more susceptible to terrorism fears 2Studies point to novel target for treating arrhythmias 2Studies point to novel target for treating arrhythmias 3
... F2α isopropyl ester (15(R)-17-phenyl trinor PGF2α ... containing both a double bond at ... group at C-15. Similar to 15(S)-latanoprost, ... a potential impurity in most commercial ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Nop1p/Fibrillarin (monoclonal) Nop1p/Fibrillarin was ... of bakers yeast, Saccharomyces cerevisiae (accession ... for yeast viability and is localized ... of Nop1p is fibrillarin (accession P22087) ...
... bind specifically to Fc regions of many ... conjugates are commonly used as affinity adsorbents ... from serum, hybridoma ascites fluids, tissue culture ... are also commonly used to capture immune ...
Biology Products: